Gyre Therapeutics (GYRE) said Monday that China's National Medical Products Administration approved its application to conduct a clinical trial evaluating pirfenidone capsules for radiation-induced lung injury, with or without immune-related pneumonitis.
The company said it expects to start the phase 2/3 trial to assess dosing and efficacy in H2 2025 at oncology and academic centers in China.
Shares of the company were down 1.8% in recent Monday trading.
Price: 8.95, Change: -0.16, Percent Change: -1.76
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。